MoonLake Immunotherapeutics (MLTX) Accumulated Expenses (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Accumulated Expenses of $21.8 million for Q1 2026, up 106.91% year-over-year from $10.5 million in Q1 2025, and up 48.49% quarter-over-quarter from $14.7 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Accumulated Expenses (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $21.8 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 106.91% year-over-year to $21.8 million; the TTM figure through Mar 2026 stood at $21.8 million (up 106.91% YoY), while the FY2025 annual figure was $14.7 million, up 21.42% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $21.8 million, up from $14.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $21.8 million in Q1 2026, with the low at $30000.0 in Q1 2022.
- The 5-year median for Accumulated Expenses is $6.9 million (2023), against an average of $8.4 million.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses plunged 50.0% in 2022, then surged 10889.46% in 2023.
- MoonLake Immunotherapeutics' Accumulated Expenses stood at $7.3 million in 2022, then decreased by 4.5% to $6.9 million in 2023, then soared by 74.59% to $12.1 million in 2024, then advanced by 21.42% to $14.7 million in 2025, then soared by 48.49% to $21.8 million in 2026.
- Business Quant data shows MLTX's Accumulated Expenses at $21.8 million in Q1 2026, $14.7 million in Q4 2025, and $21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.11 Mn |
| Mar 31, 2026 | 21.81 Mn |
| Dec 31, 2025 | 14.69 Mn |
| Sep 30, 2025 | 21.59 Mn |
| Jun 30, 2025 | 8.73 Mn |
| Mar 31, 2025 | 10.54 Mn |
| Dec 31, 2024 | 12.10 Mn |
| Sep 30, 2024 | 7.93 Mn |
| Jun 30, 2024 | 5.82 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Dec 31, 2023 | 6.93 Mn |
| Sep 30, 2023 | 6.75 Mn |
| Jun 30, 2023 | 2.62 Mn |
| Mar 31, 2023 | 3.30 Mn |
| Dec 31, 2022 | 7.26 Mn |
| Sep 30, 2022 | 4.96 Mn |
| Jun 30, 2022 | 3.07 Mn |
| Mar 31, 2022 | 30,000.00 |
| Dec 31, 2021 | 4.52 Mn |
| Sep 30, 2021 | 110,000.00 |